To assess the dynamic regulation of LAPTM4B during the acquisition of drug resistance, we collected matched tumor tissues from six patients with histologically confirmed lung adenocarcinoma, all carrying EGFR 19Del mutations (Supplementary Table S2). This evidence concerns the gene LAPTM4B and lung adenocarcinoma.